@nequalsone, thanks for keeping an eye out for us all the time....

@nequalsone, thanks for keeping an eye out for us all the time. At that early stage of the product cycle, I said it’s not a zero sum game when either ones of us (FLC, Suez or Oxymem) win new contracts because that prove that the claims behind MABR are validated. More installations mean more data and better acceptance by the broad market.

Looking at points awarded above, highest weightage is given to MABR providers who have pilot plant and/or proven installations. Now we can understand why the breakthroughs on China were so important. Track record and installations are everything in this biz.

Anyway, since that comment, thankfully FLC is pulling ahead with number of installations worldwide, especially in China, and I just sense FLC is leading the pack with Aspiral. But SUBRE and the retrofit market is where the bulge is. I wonder how Suez and Oxymem is doing on that front. Appreciate if you could flag it for us through the sleuth work of your wonderful search engine.

Thanks again.